Abstracts

Comparison of Cross-Sectional Incidence Assay Results From DBS and Plasma

Assays have been developed for cross-sectional HIV incidence estimation using plasma samples.  Large scale surveillance programs are planned using dried blood spot (DBS) specimens for incidence assessment.  However, limited information exists on the performance of HIV cross-sectional incidence assays using DBS.  This study compared results obtained from three incidence assays using plasma and DBS samples. The…

HIV Pretreatment Drug Resistance in Mexico: A Nationally Representative WHO Survey

To ensure sustainability of antiretroviral treatment (ART) programmes after ART scale up, the WHO has proposed a global standardized HIV drug resistance (DR) monitoring and surveillance strategy, including the assessment of pre-treatment HIVDR (PDR). We present the first nationally representative WHO HIV PDR survey performed in Mexico from February to July 2015. Twenty-five clinics were…

Large Cluster Clinical Isolates Show Facilitated Escape From Integrase Inhibitors

Background: Integrase inhibitors (INIs), including raltegravir (RGV), elvitegravir (EVG)  and dolutegravir (DTG) are a drug class of choice in first-line therapy. Emergent resistance to EVG and RGV include N155H and G140A/G148RHQ pathways, conferring RGV/EVG cross-resistance, and Y143RHC (RGV) and T66I/E92Q/G (EVG) pathways. To date, DTG shows a higher barrier to resistance with no reported mutations…

An Informatics Approach to Predicting Rates of Transmitted HIV-1 Drug Resistance

National transmitted HIV-1 drug resistance (TDR) rates are typically monitored through HIV surveillance data and this represents the gold-standard for determining TDR rates in various populations. However, it often requires several years to prepare data for presentation and publication resulting in long lag times between data accumulation and result dissemination. Here we present a computational…